Immatics N.V. (IMTX) stock
Close on Nov 13, 2026Market cap $856.72MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- €768.08M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -23.85%
Fundamentals
- EPS, diluted
- -1.61 EUR
- Free cash flow
- -€183.18M
- Diluted shares
- 137M
Trading
- Previous close
- $6.52
- Open
- $6.49
- Day's range
- $6.08 – $6.54
- Volume
- 586,386
- Average volume (20 days)
- 1,099,683
- Beta (5 years)
- 1.21
- RSI (14 days)
- 36.0
- Volatility (1 year)
- 55.8%
- Relative volume
- 0.78×
- WACC
- 11.1%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMTX | S&P 500 | Difference | IMTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.4% | -3.0% | −3.4 pts | ||
| 3 months | -33.4% | -2.8% | −30.6 pts | ||
| Year to date | -39.1% | +11.5% | −50.6 pts | ||
| 1 year | -36.0% | +13.5% | −49.4 pts | ||
| 3 years | -33.2% | +77.7% | −110.9 pts | -12.6% | +21.1% |
| 5 years | -45.3% | +72.6% | −117.9 pts | -11.4% | +11.5% |
Nine years at a glance
Fiscal years 2017 to 2025, EUR
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Immatics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Immatics
Biological Products, (No Diagnostic Substances)
Immatics is a biotechnology enterprise focused on research and development programs involving T-cell receptor therapies and proprietary database operations. The company develops early-stage and advanced TCER therapeutic programs alongside partner organizations. Its collaborators and commercial partners include major biopharmaceutical corporations such as Bristol Myers Squibb, Moderna, and Genmab, which participate through strategic license, development, and collaboration agreements.
Company profile, executives and historyImmatics stock: common questions
What is Immatics's stock price?
IMTX closed at $6.39 on Nov 13, 2026, down 1.99% on the day.
What is Immatics's market cap?
Immatics was worth $856.72M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is IMTX's P/E ratio?
Immatics lost money over fiscal 2025 (diluted EPS -1.61 EUR), so it has no meaningful P/E ratio.
Does Immatics pay a dividend?
No. Immatics has not paid a cash dividend over the last twelve months.
How has IMTX stock performed over the past year?
Including dividends, IMTX returned -36.0% over the past year, against +13.5% for the S&P 500.
Who are Immatics's competitors?
Companies most similar to Immatics by business, industry and size include AGMB, BNTX, BEAM, ELOX, AGEN.
See a number that looks wrong?